BMC Cancer Онкология

Real-world event-free survival with neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab in early-stage triple-negative and estrogen receptor-low, HER2-negative breast cancer

Yosuke Aoyama, Yukinori Ozaki, Masahiro Kuno, Jun Masuda, Meiko Nishimura, Mami Kurata, Lina Inagaki, Mari Hosonaga, Ippei Fukada, Emi Taniguchi, Yuri Kimura, Tetsuyo Maeda, Kazuyo Yoshida, Nami Yamashita, Takayuki Kobayashi, Toshimi Takano, Takayuki Ueno
Springer Nature · 2026-10-06 · DOI 10.1186/s12885-026-17065-0

Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.

Читать у издателя →